Cargando…

Autonomic dysfunction in patients with COVID‑19

PURPOSE: Autonomic dysfunction in patients with viral infections has been described before. In this study, we aimed to evaluate autonomic functions in patients with the coronavirus infectious disease 2019 (COVİD-19). METHODS: In this cross-sectional study, we compared 112 patients who had recovered...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdal, Yuksel, Atalar, Arife Cimen, Gunes, Taskın, Okluoglu, Tugba, Yavuz, Nurettin, Emre, Ufuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891732/
https://www.ncbi.nlm.nih.gov/pubmed/35239131
http://dx.doi.org/10.1007/s13760-022-01899-z
_version_ 1784661961130115072
author Erdal, Yuksel
Atalar, Arife Cimen
Gunes, Taskın
Okluoglu, Tugba
Yavuz, Nurettin
Emre, Ufuk
author_facet Erdal, Yuksel
Atalar, Arife Cimen
Gunes, Taskın
Okluoglu, Tugba
Yavuz, Nurettin
Emre, Ufuk
author_sort Erdal, Yuksel
collection PubMed
description PURPOSE: Autonomic dysfunction in patients with viral infections has been described before. In this study, we aimed to evaluate autonomic functions in patients with the coronavirus infectious disease 2019 (COVİD-19). METHODS: In this cross-sectional study, we compared 112 patients who had recovered from COVID-19 and 106 healthy controls. Symptoms of autonomic dysfunction were assessed with the SCOPA-AUT scale. RESULTS: Pupillomotor, urinary and sudomotor subscores of SCOPA-AUT scale were significantly higher in the COVID-19 patient group (p = 0.03, p = 0,006, p = 0.0001, respectively). There were no significant difference in terms of gastrointestinal, cardiovascular, sexual subscores and total SCOPA-AUT scores between the patient and control groups. The presence of fatigue symptom in the acute phase of COVID-19 increased the total SCOPA-AUT score by 2.2 points (p = 0.04) whereas the presence of smell loss (OR = 5.82, p = 0.01) and dyspnea (OR = 5.8, p = 0.03) were significant risk factors for pupillomotor dysfunction. The urinary, cardiovascular, sexual subscores and the total score of SCOPA-AUT scale were positively correlated with the age of the patient group. CONCLUSION: Our study suggests that many patients might have prolonged symptoms of autonomic dysfunction after the acute phase of COVID-19 that might worsen the clinical recovery.
format Online
Article
Text
id pubmed-8891732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88917322022-03-04 Autonomic dysfunction in patients with COVID‑19 Erdal, Yuksel Atalar, Arife Cimen Gunes, Taskın Okluoglu, Tugba Yavuz, Nurettin Emre, Ufuk Acta Neurol Belg Original Article PURPOSE: Autonomic dysfunction in patients with viral infections has been described before. In this study, we aimed to evaluate autonomic functions in patients with the coronavirus infectious disease 2019 (COVİD-19). METHODS: In this cross-sectional study, we compared 112 patients who had recovered from COVID-19 and 106 healthy controls. Symptoms of autonomic dysfunction were assessed with the SCOPA-AUT scale. RESULTS: Pupillomotor, urinary and sudomotor subscores of SCOPA-AUT scale were significantly higher in the COVID-19 patient group (p = 0.03, p = 0,006, p = 0.0001, respectively). There were no significant difference in terms of gastrointestinal, cardiovascular, sexual subscores and total SCOPA-AUT scores between the patient and control groups. The presence of fatigue symptom in the acute phase of COVID-19 increased the total SCOPA-AUT score by 2.2 points (p = 0.04) whereas the presence of smell loss (OR = 5.82, p = 0.01) and dyspnea (OR = 5.8, p = 0.03) were significant risk factors for pupillomotor dysfunction. The urinary, cardiovascular, sexual subscores and the total score of SCOPA-AUT scale were positively correlated with the age of the patient group. CONCLUSION: Our study suggests that many patients might have prolonged symptoms of autonomic dysfunction after the acute phase of COVID-19 that might worsen the clinical recovery. Springer International Publishing 2022-03-03 2022 /pmc/articles/PMC8891732/ /pubmed/35239131 http://dx.doi.org/10.1007/s13760-022-01899-z Text en © The Author(s) under exclusive licence to Belgian Neurological Society 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Erdal, Yuksel
Atalar, Arife Cimen
Gunes, Taskın
Okluoglu, Tugba
Yavuz, Nurettin
Emre, Ufuk
Autonomic dysfunction in patients with COVID‑19
title Autonomic dysfunction in patients with COVID‑19
title_full Autonomic dysfunction in patients with COVID‑19
title_fullStr Autonomic dysfunction in patients with COVID‑19
title_full_unstemmed Autonomic dysfunction in patients with COVID‑19
title_short Autonomic dysfunction in patients with COVID‑19
title_sort autonomic dysfunction in patients with covid‑19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891732/
https://www.ncbi.nlm.nih.gov/pubmed/35239131
http://dx.doi.org/10.1007/s13760-022-01899-z
work_keys_str_mv AT erdalyuksel autonomicdysfunctioninpatientswithcovid19
AT atalararifecimen autonomicdysfunctioninpatientswithcovid19
AT gunestaskın autonomicdysfunctioninpatientswithcovid19
AT okluoglutugba autonomicdysfunctioninpatientswithcovid19
AT yavuznurettin autonomicdysfunctioninpatientswithcovid19
AT emreufuk autonomicdysfunctioninpatientswithcovid19